| Name | Title | Contact Details |
|---|
Developing high-value, global products for patients with significant unmet medical needs in niche indications
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.
Gala Therapeutics is a medical devices company developing therapies to improve survival, quality of life, and outcomes for patients with pulmonary diseases.
Allied Research International is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.